ReviewFrontiers in cell and developmental biology2016
FXYD5: Na(+)/K(+)-ATPase Regulator in Health and Disease.
Review in Frontiers in cell and developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prognostic value of dysadherin in cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- The functions of FXYD family members in human health and disease.Genes & diseases · 2026Review
- Distinct molecular pathways leading to dosage-dependent temozolomide resistance in GBM stem cells.Cancer cell international · 2026Article
- Post-translational modifications of na+/K+-atpase subunits: regulatory mechanisms and functional implications.Frontiers in cell and developmental biology · 2026Review
- Article
- Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.Future science OA · 2025Article
- Cancer-Type-Specific DNA Methylation Is a Source of Vulnerability in Liver Cancer Cells.Cancer science · 2025Article
- miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion.Molecular biotechnology · 2024Article
- Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.Heliyon · 2024Article
- Smoking-associated gene expression alterations in nasal epithelium reveal immune impairment linked to lung cancer risk.Genome medicine · 2024Article
- Article
- Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.Histology and histopathology · 2021Article
- Article
- FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.British journal of cancer · 2019Article
- A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody.Glycobiology · 2019Article
- Exploring the role of stromal osmoregulation in cancer and disease using executable modelling.Nature communications · 2018Article
- Cytokine-Ion Channel Interactions in Pulmonary Inflammation.Frontiers in immunology · 2017Review
- FXYD8, a Novel Regulator of Renal NaFrontiers in physiology · 2017Article
- FXYD5 Is an Essential Mediator of the Inflammatory Response during Lung Injury.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FXYD5 (Dysadherin, RIC) is a single span type I membrane protein that plays multiple roles in regulation of cellular functions. It is expressed in a variety of epithelial tissues and acts as an auxiliary subunit of the Na(+)/K(+)-ATPase. During the past decade, a correlation between enhanced expression of FXYD5 and tumor progression has been established for various tumor types. In this review, current knowledge on FXYD5 is discussed, including experimental data on the functional effects of FXYD5 on the Na(+)/K(+)-ATPase. FXYD5 modulates cellular junctions, influences chemokine production, and affects cell adhesion. The accumulated data may provide a basis for understanding the molecular mechanisms underlying FXYD5 mediated phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.